Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

Overview of attention for article published in BMC Gastroenterology, April 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (51st percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 2,210 followers.

【薬剤経済学研究】化学療法抵抗性転移性大腸癌患者において、TAS-102+ベバシズマブ療法は、TAS-102単剤療法と比較して、$21,534/QALYの増分費用効果比を有していた。 #ペ読 https://t.co/cbcXyINt54

New article: Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer https://t.co/5HPtXuMGSj #colorectalcancer #oncology https://t.co/ZPbEHu8p3A

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.